Head to Head Review: Cerus Corporation (CERS) vs. Endologix (ELGX)

Endologix (NASDAQ: ELGX) and Cerus Corporation (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Valuation and Earnings

This table compares Endologix and Cerus Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Endologix $190.75 million 1.86 -$54.38 million ($0.94) -4.53
Cerus Corporation $36.83 million 7.41 -$61.75 million ($0.61) -4.10

Endologix has higher revenue and earnings than Cerus Corporation. Endologix is trading at a lower price-to-earnings ratio than Cerus Corporation, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Endologix has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Cerus Corporation has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.

Insider & Institutional Ownership

62.6% of Cerus Corporation shares are owned by institutional investors. 3.9% of Endologix shares are owned by insiders. Comparatively, 7.4% of Cerus Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Endologix and Cerus Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -40.77% -46.32% -13.67%
Cerus Corporation -164.39% -120.31% -65.38%

Analyst Recommendations

This is a summary of current recommendations and price targets for Endologix and Cerus Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 10 0 0 2.00
Cerus Corporation 0 0 4 0 3.00

Endologix currently has a consensus price target of $6.33, indicating a potential upside of 48.67%. Cerus Corporation has a consensus price target of $7.25, indicating a potential upside of 190.00%. Given Cerus Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Cerus Corporation is more favorable than Endologix.


Cerus Corporation beats Endologix on 8 of the 13 factors compared between the two stocks.

Endologix Company Profile

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply